Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 4/20 | 0.64 |
| ▸ | ACLY | P53396 | 2/20 | 0.64 |
| ▸ | MCL1 | Q07820 | 12/20 | 0.60 |
| ▸ | BCL2A1 | Q16548 | 6/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276451 | 0.83 | ACLY (0.71) | ACLYMCL1BCL2A1KDM4EALDH1A1 | |
| SCHEMBL18151922 | 0.83 | MCL1 (0.82) | METAP2ACLYMCL1BCL2A1 | |
| SCHEMBL4565923 | 0.79 | METAP2 (0.69) | METAP2ACLYMCL1BCL2A1KDM4E | |
| SCHEMBL3984242 | 0.78 | METAP2 (1.00) | METAP2ACLYMCL1BCL2A1KDM4E | |
| SCHEMBL3806499 | 0.78 | ACLY (0.69) | METAP2ACLYMCL1KDM4EALDH1A1 | |
| SCHEMBL21931063 | 0.78 | ACLY (1.00) | ACLYMCL1 | |
| SCHEMBL3810580 | 0.78 | ACLY (0.70) | ACLYMCL1 | |
| SCHEMBL3988633 | 0.78 | ACLY (0.69) | METAP2ACLYMCL1 | |
| SCHEMBL2271008 | 0.78 | KMT2A (0.56) | METAP2ACLYMCL1KDM4EALDH1A1 | |
| SCHEMBL5147679 | 0.78 | KMT2A (0.56) | METAP2ACLYMCL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | METAP2 1126/4885ACLY 653/4885MCL1 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.